Novo Nordisk (NVO -2.1%) shares slip after announcing the FDA extended the regulatory review...

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor

Novo Nordisk (NVO -2.1%) shares slip after announcing the FDA extended the regulatory review period by three months for the drug maker's ultra-long-acting insulins degludec and insulin degludec/insulin aspart for the treatment of type 1 and type 2 diabetes.